

Announcement Summary

Entity name

ATOMO DIAGNOSTICS LIMITED

Announcement Type

New announcement

Date of this announcement

13/7/2023

The Proposed issue is:

C An offer of securities under a securities purchase plan

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
AT1	ORDINARY FULLY PAID	76,388,888

+Record date

12/7/2023

Offer closing date

1/8/2023

+Issue date

8/8/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

ATOMO DIAGNOSTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ABN

37142925684

1.3 ASX issuer code

AT1

1.4 The announcement is

Solution New announcement

1.5 Date of this announcement

13/7/2023

1.6 The Proposed issue is:

C An offer of +securities under a +securities purchase plan



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1a Conditions

Approval/Condition +Security holder approval Date for determination 31/8/2023

Is the date estimated or actual? 𝔅 Estimated ** Approval received/condition met?

Comments

Refer Placement and SPP announcement lodged on 13 July 2023. AT1 has applied to ASX for a LR 7.1 waiver to permit the issue of new shares under the SPP without shareholder approval. In the event that the waiver is not granted, AT1 will seek shareholder approval at an EGM to issue the new shares under the SPP, along with any shortfall under the SPP.



Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

AT1 : ORDINARY FULLY PAID

Details of +securities proposed to be issued

ASX +security code and description

AT1 : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

76,388,888

Is the minimum acceptance unit based or dollar based? ⓒ Dollar based (\$)

Please enter the minimum acceptance value

\$ 1,000

Is the maximum acceptance unit based or dollar based? ☑ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000



Describe all the applicable parcels available for this offer in number of securities or dollar value

\$1,000, \$2,500, \$7,500, \$10,000, \$15,000, \$20,000, \$30,000

Offer price details

Has the offer price been determined? $\ensuremath{\mathfrak{C}}$ Yes

In what currency will the offer
be made?What is the offer price per
+security?AUD - Australian DollarAUD 0.03600

Oversubscription & Scale back details

Describe the scale back arrangements

Applications may be scaled back at the absolute discretion of the Company.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

C Yes

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

13/7/2023

4C.2 +Record date

12/7/2023

4C.3 Date on which offer documents will be made available to investors

18/7/2023

4C.4 Offer open date

18/7/2023

4C.5 Offer closing date

1/8/2023

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

8/8/2023



Part 4D - Listing Rule requirements

4D.1a (i) How many +securities are proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

All of the new shares proposed to be issued under the SPP, subject to ASX granting a waiver of LR 7.1.

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer? $\ensuremath{\mathfrak{C}}$ Yes

4E.1a Who is the lead manager/broker?

Bell Potter

4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The lead manager's fees comprise 6% of the funds raised under the SPP offer, with the exception of funds received from GZ Family Office.

4E.2 Is the proposed offer to be underwritten?

🕑 No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer



Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

To fund hCG Pregnancy Test sales & marketing (ANZ/US); Iron Deficiency Test registration & commercial activity (ANZ/UK and Europe); POC Technology (OEM) business development; Product development (app, digital, Vitamin D); and working capital requirements.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? \ref{No} No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

Shareholders who are not resident in Australia or New Zealand or the United Kingdom will not be able to participate in the SPP.

4F.3 URL on the entity's website where investors can download information about the proposed offer

https://investors.atomodiagnostics.com/investor-centre/?page=asx-announcements

4F.4 Any other information the entity wishes to provide about the proposed offer